Ischemic tissue cell therapy
AssigneeUniversity of South Florida
InventorsPaul R. Sanberg, Alison E. Willing
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.
Claims19
A therapeutic comprising:
- a composition further comprising a CD14+ monocyte lineage cell enriched therapeutic cell population.
A method of treating a neurodegenerative disease, nerve damage, or the effects of nerve damage or neurodegeneration comprising:
- obtaining a therapeutic comprising a monocyte lineage cell enriched therapeutic cell population;
- administering via transplantation an effective amount of the therapeutic to a patient in need thereof.
A method of treating a human patient with a circulatory disorder comprising
- obtaining a therapeutic comprising a monocyte lineage cell enriched therapeutic cell population;
- administering via transplantation an effective amount of the therapeutic to the patient.
The method of claim 17, wherein the CD14+ cells are CD16+ cells.
The method of claim 19, wherein the CD14+ cells are CD16+ cells.
Dependencies are inferred from the claim text.